NEK2 regulates stem-like properties and predicts poor prognosis in hepatocellular carcinoma.

NEK2 has been estimated to play an important role in cancer progression. However, its relevance in hepatocellular carcinoma (HCC) has not yet been explored. Immunohistochemistry revealed NEK2 expression was upregulated in HCC. NEK2-positive hepatocellular carcinoma patients were associated with poor prognosis after surgery compared with NEK2-negative patients based on Kaplan-Meier curves. Deletion of NEK2 reduced self-renewal properties and chemotherapeutic resistance, and decreased the stemness associated genes in cell lines. NEK2 was associated with unfavorable outcomes in HCC patients, and was revealed to regulate self-renewal property by means of Wnt/β-catenin signaling, and chemotherapeutic resistance by preferential regulation of the expression of ABCG2 and ALDH1A1 in HCC cells.

[1]  S. Monga.  β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis. , 2015, Gastroenterology.

[2]  E. Hatano,et al.  Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma , 2015, Clinical Cancer Research.

[3]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[4]  A. Fry,et al.  Overexpression of the Nek2 kinase in colorectal cancer correlates with beta‐catenin relocalization and shortened cancer‐specific survival , 2014, Journal of surgical oncology.

[5]  F. Zhan,et al.  NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma , 2014, Oncotarget.

[6]  P. Boutros,et al.  Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells , 2014, Oncogene.

[7]  Shize Yang,et al.  Examining Nek2 as a better proliferation marker in non-small cell lung cancer prognosis , 2014, Tumor Biology.

[8]  W. Nelson,et al.  Nek2 phosphorylates and stabilizes β-catenin at mitotic centrosomes downstream of Plk1 , 2014, Molecular biology of the cell.

[9]  P. Chieffi,et al.  The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival , 2013, Nucleic acids research.

[10]  H. Taniguchi,et al.  Cellular reprogramming and hepatocellular carcinoma development. , 2013, World journal of gastroenterology.

[11]  Junhua Wu,et al.  Expression of Potential Cancer Stem Cell Marker ABCG2 is Associated with Malignant Behaviors of Hepatocellular Carcinoma , 2013, Gastroenterology research and practice.

[12]  C. Heeschen,et al.  Standing out from the crowd: cancer stem cells in hepatocellular carcinoma. , 2013, Cancer cell.

[13]  X. Wang,et al.  Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma , 2013, Hepatology.

[14]  S. Giordano,et al.  MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? , 2013, Hepatology.

[15]  F. Zhan,et al.  NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. , 2013, Cancer cell.

[16]  M. McCarter,et al.  ALDH1A Isozymes are Markers of Human Melanoma Stem Cells and Potential Therapeutic Targets , 2012, Stem cells.

[17]  Vindhya Koppaka,et al.  Aldehyde Dehydrogenase Inhibitors: a Comprehensive Review of the Pharmacology, Mechanism of Action, Substrate Specificity, and Clinical Application , 2012, Pharmacological Reviews.

[18]  Han Liu,et al.  Nek2A contributes to tumorigenic growth and possibly functions as potential therapeutic target for human breast cancer , 2012, Journal of cellular biochemistry.

[19]  Y. Huang,et al.  The Beta2-Adrenergic Receptor is a Potential Prognostic Biomarker for Human Hepatocellular Carcinoma After Curative Resection , 2012, Annals of Surgical Oncology.

[20]  Jian Zhang,et al.  Induction of cancer cell stemness by chemotherapy , 2012, Cell cycle.

[21]  Wei-dong Li,et al.  Abnormal expression of Nek2 and β‐catenin in breast carcinoma: clinicopathological correlations , 2011, Histopathology.

[22]  S. Jacob,et al.  Role of cancer stem cells in hepatocarcinogenesis , 2011, Genome Medicine.

[23]  X. Wang,et al.  A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. , 2010, Cancer research.

[24]  X. Guan,et al.  Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion , 2010, Gut.

[25]  Yingjie Yu,et al.  The Wnt/β-catenin pathway regulates growth and maintenance of colonospheres , 2010, Molecular Cancer.

[26]  C. Cavard,et al.  EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. , 2010, Journal of hepatology.

[27]  P. Chow,et al.  Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. , 2009, The Lancet. Oncology.

[28]  X. Wang,et al.  EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.

[29]  D. Pei.  Regulation of Pluripotency and Reprogramming by Transcription Factors* , 2009, Journal of Biological Chemistry.

[30]  S. Bates,et al.  ABCG2: a perspective. , 2009, Advanced drug delivery reviews.

[31]  Dianqing Wu,et al.  Wnt3a-Mediated Formation of Phosphatidylinositol 4,5-Bisphosphate Regulates LRP6 Phosphorylation , 2008, Science.

[32]  Liang Tang,et al.  Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. , 2008, Cancer research.

[33]  D. Balicki.  Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. , 2007, Cell stem cell.

[34]  Xin Wei Wang,et al.  Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. , 2007, Cancer research.

[35]  E. F. da Cruz e Silva,et al.  Alternative Splicing Controls Nuclear Translocation of the Cell Cycle-regulated Nek2 Kinase* , 2007, Journal of Biological Chemistry.

[36]  I. Ng,et al.  Identification and characterization of tumorigenic liver cancer stem/progenitor cells. , 2007, Gastroenterology.

[37]  V. Mazzaferro,et al.  Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma , 2007, Hepatology.

[38]  A. Pyle,et al.  Defining the Role of Wnt/β‐Catenin Signaling in the Survival, Proliferation, and Self‐Renewal of Human Embryonic Stem Cells , 2005, Stem cells.

[39]  H. Clevers,et al.  Wnt signalling in stem cells and cancer , 2005, Nature.

[40]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[41]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[42]  J. Y. Lee,et al.  Identification of brain tumour initiating cells using the stem cell marker aldehyde dehydrogenase. , 2014, European journal of cancer.

[43]  H. Saavedra,et al.  Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance. , 2014, Frontiers in bioscience.

[44]  Ming-Yu Yang,et al.  Blockage of a miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas. , 2014, Cancer letters.

[45]  K. Mimori,et al.  Up-regulation of NEK2 by MicroRNA-128 Methylation is Associated with Poor Prognosis in Colorectal Cancer , 2013, Annals of Surgical Oncology.

[46]  P. Casey,et al.  beta-Catenin is a Nek2 substrate involved in centrosome separation. , 2008, Genes & development.

[47]  P. Greengard,et al.  Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor , 2004, Nature Medicine.

[48]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.